(vi) 10m unlisted options
10m unlisted options were issued for lead advisory services following the $5m placement completed on 17 April 2018.
The options are exercisable at $0.15 on or before 30 June 2021.
These costs are included in costs of capital for the year ended 30 June 2018.
Listed options
(vii) 56 million listed options
Pursuant to the capital raising, completed on 12 May 2016, the Company issued 56,818,380 listed options as free attaching options at
one for every three shares issued, on 6 October 2016.
(viii) 35 million listed options
On 10 November 2016, 35 million listed options were issued to consultants and advisors of the Company as detailed in the Notice of
General Meeting issued on 26 August 2016, and as approved by shareholders on 27 September 2016. The options are exercisable at
$0.065 each expiring on or before 30 June 2019.
The following table lists the inputs to the model used for valuation of options:
(c) Issue of Performance Rights
(i) 32.5 million and 4 million Performance Rights
Following shareholder approval at the General Meeting held on 27 September 2016, 32.5 million unlisted Performance Rights were
issued to Directors on 17 October 2016 and a further 4 million were issued on 23 December 2016 as approved at the Annual General
Meeting on 29 November 2016.
The principal terms and conditions of the Performance Rights include, continuous service in their capacity as Director or Executive to
the Company, or as otherwise agreed and are subject to vesting milestones as detailed below.
The following table lists the inputs to the model used for valuation of options:
Notes to the Financial Statements
mgcpharma.com.au
58